Dublin, Ireland, 9th March, 2015 – ICON plc, (NASDAQ: ICLR) a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, today announced the launch of a new Medical Device & Diagnostics Research group focused on the unique requirements of the medical device and diagnostics industry.
The new group combines the medical and regulatory device and diagnostic expertise of Aptiv Solutions, which ICON acquired in 2014, with ICON’s global clinical development and commercialisations solutions. Device and diagnostic manufacturers can now benefit from an expanded suite of services that support the full product lifecycle, including global clinical trial execution, health economics and pricing and market access solutions.
“The device and diagnostic development model can differ significantly from that of pharmaceutical companies, both in complexity and time to market,” commented Elizabeth Thiele, President, ICON Commercialisation & Outcomes. “Operating under specific medical device SOPs and ISO certification, our new Medical Device & Diagnostics Research team has the expertise and flexibility to help manufacturers take time and cost from their development programmes and maximise the value of their products.”
ICON’s Medical Device & Diagnostics Research group will be led by Vicki Anastasi, Vice President, Medical Device & Diagnostic Research, who has over 20 years of medical device and diagnostics experience. The group is comprised of a team of dedicated project managers and clinical operations professionals as well as regulatory and strategic consultants.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Gilead Shares Final Data from Phase III MYR301 Trial of Bulevirtide in Chronic Hepatitis Delta Virus
May 7th 2025Long-term results from the study show 90% of patients with chronic HDV who achieved undetectable HDV RNA at 96 weeks of treatment remained undetectable for nearly 2 years post-treatment.